It is well-established that Human Papillomavirus (HPV), the primary cause of cervical cancer can be detected in first-void urine. The study by Laura Téblick (University of Antwerp, Belgium...
We recently had the opportunity to interview Dr. Severien Van Keer, a post-doc researcher at the VAXINFECTIO research group, at the University of Antwerp.
What a milestone! 8 years and counting. To celebrate our 8th anniversary, we asked our team members to describe Novosanis and their experience in unique words. Teamwork and Innovation were...
In view of the spread of Covid-19 (coronavirus) in our country and across the world, our topmost priority is the health and safety of all our customers and employees. Our team will be...
Researchers at The Sciensano Institute in Belgium will be using urine collected through Colli-Pee ® to understand Chlamydia presence in all ages and genders in the Belgium population.
Novosanis has been co-awarded a CASUS grant, which allows to build a next-generation Colli-Pee ® that will be used in a molecular screening solution for cervical cancer.
Novosanis receives grant from Interreg CrossCare to build a next-generation of its unique and patented intradermal drug delivery device, VAX-ID, in collaboration with living labs Happy...
A wrap to an exciting and eventful week! Our Product designer, Alejandra Ríos Cortés, represented Novosanis at the Royal Mission, an initiative led by Princess Astrid of Belgium, to boost...
This website uses cookies to help us give you the best experience when you visit our website. Read our cookie policy to learn more about the cookies we use. By continuing to use this website, you consent to the use of these cookies.
Novosanis
